WO2003011903A3 - Identification of specific tumor antigens by means of the selection of cdna libraries with sera - Google Patents

Identification of specific tumor antigens by means of the selection of cdna libraries with sera Download PDF

Info

Publication number
WO2003011903A3
WO2003011903A3 PCT/IT2002/000490 IT0200490W WO03011903A3 WO 2003011903 A3 WO2003011903 A3 WO 2003011903A3 IT 0200490 W IT0200490 W IT 0200490W WO 03011903 A3 WO03011903 A3 WO 03011903A3
Authority
WO
WIPO (PCT)
Prior art keywords
selection
sera
identification
tumor antigens
technique
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2002/000490
Other languages
French (fr)
Other versions
WO2003011903A2 (en
Inventor
Franco Felici
Olga Minenkova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenton Srl
Original Assignee
Kenton Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2002330743A priority Critical patent/AU2002330743A1/en
Priority to JP2003517093A priority patent/JP2005508309A/en
Priority to KR10-2004-7000954A priority patent/KR20040049835A/en
Priority to MXPA04000652A priority patent/MXPA04000652A/en
Priority to US10/484,800 priority patent/US20050069556A1/en
Priority to HU0400661A priority patent/HUP0400661A3/en
Application filed by Kenton Srl filed Critical Kenton Srl
Priority to CA002453939A priority patent/CA2453939A1/en
Priority to EP02767839A priority patent/EP1438334A2/en
Publication of WO2003011903A2 publication Critical patent/WO2003011903A2/en
Anticipated expiration legal-status Critical
Publication of WO2003011903A3 publication Critical patent/WO2003011903A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method is described for the identification of specific tumour antigens by means of the selection of CND display libraries by using sera, characterised in that said selection is accomplished with the phage display technique, and in particular said selection is accomplished by means of the SEREX technique (serological analysis of autologous tumor antigens through the expression of recombinant cDNA). The method according to the invention described herein advantageously combines the SEREX approach with the potency of the phage display technique defined above, at the same time avoiding the drawbacks characteristic of the SEREX technique. The so identified antigens are useful for the preparation of medicaments for the treatment of tumors.
PCT/IT2002/000490 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera Ceased WO2003011903A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2003517093A JP2005508309A (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by selection of cDNA libraries in serum and use of the antigens in tumor treatment
KR10-2004-7000954A KR20040049835A (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera and the use of said antigens in the treatment of tumors
MXPA04000652A MXPA04000652A (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera and the use of said antigena in the treatment of tumors.
US10/484,800 US20050069556A1 (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera and the use of said antigena in the treatment of tumors
HU0400661A HUP0400661A3 (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection os cdna libraries with sera and the use of said antigena in the treatment of tumors
AU2002330743A AU2002330743A1 (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera
CA002453939A CA2453939A1 (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera
EP02767839A EP1438334A2 (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000413 WO2003011902A1 (en) 2001-07-27 2001-07-27 Identification of specific tumour antigens by selection of cdna libraries with sera
ITPCT/IT01/00413 2001-07-27

Publications (2)

Publication Number Publication Date
WO2003011903A2 WO2003011903A2 (en) 2003-02-13
WO2003011903A3 true WO2003011903A3 (en) 2004-05-06

Family

ID=11133709

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IT2001/000413 Ceased WO2003011902A1 (en) 2001-07-27 2001-07-27 Identification of specific tumour antigens by selection of cdna libraries with sera
PCT/IT2002/000490 Ceased WO2003011903A2 (en) 2001-07-27 2002-07-25 Identification of specific tumor antigens by means of the selection of cdna libraries with sera

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IT2001/000413 Ceased WO2003011902A1 (en) 2001-07-27 2001-07-27 Identification of specific tumour antigens by selection of cdna libraries with sera

Country Status (10)

Country Link
US (1) US20050069556A1 (en)
EP (1) EP1438334A2 (en)
JP (1) JP2005508309A (en)
KR (1) KR20040049835A (en)
AU (1) AU2002330743A1 (en)
CA (1) CA2453939A1 (en)
HU (1) HUP0400661A3 (en)
MX (1) MXPA04000652A (en)
PL (1) PL369291A1 (en)
WO (2) WO2003011902A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207251D0 (en) * 2002-03-27 2002-05-08 Isis Innovation Lymphoma-associated antigens
US20040248109A1 (en) * 2003-06-09 2004-12-09 Lawrence Greenfield Methods for selecting protein binding moieties
ITRM20040489A1 (en) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti LONG PENTRAXINE PTX3 DEGLICOSILATA OR DESIALIDATA.
CN100428254C (en) * 2006-07-20 2008-10-22 上海交通大学 A method for computer-aided screening of cross-reactive antigens
EP2108656A1 (en) 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
KR20170026624A (en) * 2014-07-07 2017-03-08 알러간, 인코포레이티드 Method of detecting cleaved snap25 in tissue samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061790A1 (en) * 1999-04-14 2000-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High sensitivity phage display biomolecule detection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061790A1 (en) * 1999-04-14 2000-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High sensitivity phage display biomolecule detection

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BEGHETTO ELISA ET AL: "Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries.", INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 31, no. 14, December 2001 (2001-12-01), pages 1659 - 1668, XP001063313, ISSN: 0020-7519 *
HALUSKA PAUL JR ET AL: "Interaction between human topoisomerase I and a novel RING finger/arginine-serine protein.", NUCLEIC ACIDS RESEARCH, vol. 27, no. 12, 15 June 1999 (1999-06-15), pages 2538 - 2544, XP002193382, ISSN: 0305-1048 *
JAEGER D ET AL: "CANCER-TESTIS ANTIGENS AND ING1 TUMOR SUPPRESSOR GENE PRODUCT ARE BREAST CANCER ANTIGENS: CHARACTERIZATION OF TISSUE-SPECIFIC ING1 TRANSCRIPTS AND A HOMOLOGUE GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 15 December 1999 (1999-12-15), pages 6197 - 6204, XP000986298, ISSN: 0008-5472 *
JAEGER D ET AL: "IDENTIFICATION OF A TISSUE-SPECIFIC PUTATIVE TRANSCRIPTION FACTOR IN BREAST TISSUE BY SEROLOGICAL SCREENING OF A BREAST CANCER LIBRARY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 5, 1 March 2001 (2001-03-01), pages 2055 - 2061, XP001053562, ISSN: 0008-5472 *
MIKAWA Y G ET AL: "Surface display of proteins on bacteriophage lambda heads.", JOURNAL OF MOLECULAR BIOLOGY, vol. 262, no. 1, 1996, pages 21 - 30, XP002203952, ISSN: 0022-2836 *
SAHIN UGUR ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 25, 1995, 1995, pages 11810 - 11813, XP002193381, ISSN: 0027-8424 *
SANTINI CLAUDIA ET AL: "Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda.", JOURNAL OF MOLECULAR BIOLOGY, vol. 282, no. 1, 1998, pages 125 - 135, XP002203954, ISSN: 0022-2836 *
SIOUD MOULDY ET AL: "Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 3, March 2001 (2001-03-01), pages 716 - 725, XP002193380, ISSN: 0014-2980 *
STERNBERG NAT ET AL: "Display of peptides and proteins on the surface of bacteriophage lambda.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 5, 1995, 1995, pages 1609 - 1613, XP002203953, ISSN: 0027-8424 *
TURECI O ET AL: "SEROLOGICAL ANALYSIS OF HUMAN TUMOR ANTIGENS: MOLECULAR DEFINITION AND IMPLICATIONS", MOLECULAR MEDICINE TODAY, ELSEVIER, CAMBRIDGE, GB, vol. 3, no. 8, August 1997 (1997-08-01), pages 342 - 349, XP000985587, ISSN: 1357-4310 *
YANG FAN ET AL: "Novel fold and capsid-binding properties of the lambda-phage display platform protein gpD.", NATURE STRUCTURAL BIOLOGY, vol. 7, no. 3, March 2000 (2000-03-01), pages 230 - 237, XP001063314, ISSN: 1072-8368 *

Also Published As

Publication number Publication date
WO2003011902A1 (en) 2003-02-13
HUP0400661A3 (en) 2008-03-28
HUP0400661A2 (en) 2005-01-28
CA2453939A1 (en) 2003-02-13
JP2005508309A (en) 2005-03-31
EP1438334A2 (en) 2004-07-21
KR20040049835A (en) 2004-06-12
PL369291A1 (en) 2005-04-18
US20050069556A1 (en) 2005-03-31
AU2002330743A1 (en) 2003-02-17
WO2003011903A2 (en) 2003-02-13
MXPA04000652A (en) 2004-03-19

Similar Documents

Publication Publication Date Title
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
AU2002355677A1 (en) Antigenic polypeptides
NO20033285D0 (en) FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2005058937A3 (en) A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
BR9908823A (en) Lung cancer therapy and diagnosis compounds and processes
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
SI0970126T1 (en) Novel method for the production of antihuman antigen receptors and uses thereof
DK1259547T3 (en) HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
PL392964A1 (en) Hyperimmune serum reactive antigen, the use of this antigen for the production of a pharmaceutical formulation, fragment of the hiperimmune antigen, antigen auxiliary epitopes, a vaccine containing the hyperimmune serum reactive antigen, formulation containing antibodies, process for the preparation of this formulation, the use of the formulation for the treatment of staphylococcal infections, and screening method
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
ATE233102T1 (en) METHOD AND COMPOSITION FOR REDESIGNING MULTI-EPITOPIC ANTIGENS TO INITIATE THE IMMUNE RESPONSE
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
WO2003010199A3 (en) Identification of specific tumour antigens by means of the selection of cdna libraries with sera and the use of said antigens in diagnostic imaging techniques
WO2003011903A3 (en) Identification of specific tumor antigens by means of the selection of cdna libraries with sera
MY141459A (en) Recombinant anti-idiotypic antibodies
ID29405A (en) NEW SART-3 TUMOR ANTIGENE PROTEINS AND THEIR ANTIGENT TUMOR PEPTIDES
UA83989C2 (en) Isolated peptide for promoting anti-tumor immune response, pharmaceutical composition based thereon and use thereof
AU3931599A (en) Basb019 proteins and genes from (moraxella catarrhalis), antigens, antibodies, and uses
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002767839

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2453939

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047000954

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000652

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003517093

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020047000954

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002767839

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10484800

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002767839

Country of ref document: EP